Clovis Oncology (CLVS) Stock: The Low Down On Approval

Clovis Oncology (NASDAQ:CLVS) On Monday, Clovis Oncology stock closed higher by 9% after it announced that the FDA had approved its drug. The drug in question is known as rucaparib – to be marketed as Rubraca. This was for early approval of rucaparib, which is used to treat patients with advanced ovarian cancer. The stock … Read more

Sarepta Therapeutics (SRPT) Stock: Here’s What You Need To Know

Sarepta Therapeutics (NASDAQ:SRPT) On Monday, Sarepta’s stock closed the day up 73.85% after the company announced that the FDA had given its drug Eteplirsen FDA approval. More specifically, the company filed for accelerated approval. In other words, drugs can be approved after only completing a phase 2 study if the results show that a surrogate … Read more

Biotech Stock News (RXII) (CLVS) (AZN)

Rxi Pharmaceuticals (NASDAQ:RXII) On May 3, 2016 Rxi Pharmaceuticals announced that it had entered into a license agreement with Thera NeuroPharma for the treatment of ALS or Lou Gherig’s Disease. ALS stands for amyotrophic lateral sclerosis, and is a debilitating disease where nerves in the muscles breakdown reducing/eliminating movement. Rxi entered the agreement with this … Read more

Biotech Stock News (CLVS)(SNTA)

Clovis Oncology (NASDAQ:CLVS) On Tuesday April 13, 2016 Clovis Oncology announced that the FDA advisory panel concluded that the company’s drug, Rociletinib, had insufficient data to warrant approval. Not only did the FDA panel advise against approval, it shot down the drug with a vote of 12 “against and 1 “for” approval. This was the … Read more